https://www.selleckchem.com/
an important component of patient selection for advanced heart failure therapies. Addressing these specific components may help improve access to advanced therapies and post-LVAD outcomes.Determination of circadian phase is required to diagnose and treat circadian abnormalities, but the measurement of dim light melatonin onset (DLMO), the most common phase marker, is laborious. As sleep timing reflects circadian phase, measurement of sleep markers (e.g., sleep onset, sleep midpoint, sleep offset) provides a simple way to estimate DLMO. The study aim was to
Like
Comment
Share
